Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial Reuters
Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial - Reuters
In short
Eli Lilly's next-generation drug has outperformed Ozempic in a clinical trial, showing superior results in both weight loss and blood sugar control. The findings highlight the potential of Lilly's new treatment within the competitive market for diabetes and weight management therapies.
Key points
- Eli Lilly's next-generation drug has outperformed Ozempic in a clinical trial, showing su…: Eli Lilly's next-generation drug has outperformed Ozempic in a clinical trial, showing superior results in both weight loss and blood sugar control.
- The findings highlight the potential of Lilly's new treatment within the competitive mark…: The findings highlight the potential of Lilly's new treatment within the competitive market for diabetes and weight management therapies.